Evidence map›Paper›PMID 40115467›Full record

ArticleCentral European journal of urology2024

MRI-derived PRECISE score for predicting pathologically-confirmed progression in prostate cancer patients on active surveillance.

Filippo Carletti, Filippo Crimì, Gianmarco Randazzo, Giuseppe Reitano, Giovanni Basso, Ermanno Maria Segreto, Salvatore Carrozza, Francesca Sattin, Matteo Todisco, Giovanni Betto and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Central European journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Filippo CarlettiDepartment of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy.
Filippo CrimìDepartment of Radiology, University of Padova, Padova, Italy.
Gianmarco RandazzoDepartment of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy.
Giuseppe ReitanoDepartment of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy.
Giovanni BassoDepartment of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy.
Ermanno Maria SegretoDepartment of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy.
Salvatore CarrozzaDepartment of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy.
Francesca SattinDepartment of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy.
Matteo TodiscoDepartment of Radiology 2, University Hospital of Padova, Padova, Italy.
Giovanni BettoDepartment of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy.
Giacomo NovaraDepartment of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy.
Fabrizio Dal MoroDepartment of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy.
Fabio ZattoniDepartment of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The utilization of magnetic resonance imaging (MRI) in active surveillance (AS) of prostate cancer (PCa) remains a topic of debate. The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) scoring system is used to evaluate the progression of MRI lesions in men undergoing AS.This study aims to evaluate the predictive capacity of the PRECISE score in monitoring PCa patients on AS. Material and methods: A cohort of 63 men enrolled in an AS program between 2017 and 2021 was analyzed. Sequential MRIs within the AS protocol were assessed by a specialized radiologist using the PRECISE score. Data on biopsy outcomes, pathological progression, and treatment progression were documented. The relationship between progression and the PRECISE score was examined. Univariate logistic and Cox regression analyses were conducted to determine the baseline clinical and mpMRI parameters associated with disease progression. Results: The cohort exhibited ISUP progression and biopsy progression rates of 27.6% (16/63) and 48.3% (28/63), respectively. At the second MRI, a PRECISE score exceeding 3 was observed in 31 patients (53.4%), with 25 patients (43.1%) showing new lesions. Overall, 23 patients (39.7%) underwent active treatment during a median follow-up of 117 months. The PRECISE score emerged as the sole predictor, in univariate analysis, of ISUP progression (OR: 3.2, IQR: 1.1-9.7, p = 0.04), biopsy progression (OR: 3.2, IQR: 1.1-9.7, p = 0.03), and active treatment (HR: 1.1, IQR: 1.0-1.6, p = 0.05). Conclusions: The PRECISE scoring system facilitates the identification of patients at risk of ISUP and biopsy progression within an AS protocol utilizing mpMRI. These findings underscore the significance of mpMRI in AS.

Indexed as

active surveillanceASfollow upmpMRIMRIPCaPRECISEPRECISE scorePRECISE scoring systemprostateprostate cancer

Identifiers

PMID40115467
PMCPMC11921959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.